文献速递瓣膜外科

快速部署主动脉瓣的长期结局:TRITON试验5年数据

Long-term outcomes of a rapid deployment aortic valve: data up to 5 years.
PubMed 文献 · Eur J Cardiothorac Surg · 2017-01-01

TRITON是一项前瞻性研究,评估Edwards INTUITY快速部署主动脉瓣置换系统的安全性和有效性。共纳入295例主动脉瓣狭窄患者,287例接受研究瓣膜。5年结果显示,孤立AVR和合并AVR的生存率分别为85.7±3.4%和75.2±4.9%,瓣膜相关死亡免除率为98.2±0.8%,血流动力学表现良好。

要点

  • 快速部署主动脉瓣5年生存率孤立组85.7±3.4%,合并组75.2±4.9%。
  • 5年瓣膜相关死亡免除率98.2±0.8%。
  • 5年有效瓣口面积1.6±0.3 cm²,平均压差10.5±5.4 mmHg。

核心结论

  • TRITON试验5年结局显示Edwards INTUITY快速部署主动脉瓣置换具有可接受的长期安全性和优异的血流动力学表现。

研究设计与样本

  • TRITON为前瞻性设计研究,纳入295例主动脉瓣狭窄患者,其中287例接受研究瓣膜。
  • 收集 procedural、早期(≤30天)和晚期(>30天)结局,瓣膜血流动力学由独立超声核心实验室评估,临床事件由独立临床事件委员会裁定。

主要发现

  • 平均年龄75.3±6.7岁,158例接受孤立AVR,129例接受AVR合并其他手术。
  • 5年生存率孤立AVR为85.7±3.4%,合并AVR为75.2±4.9%。
  • 5年瓣膜相关死亡免除率为98.2±0.8%。
  • 5年有效瓣口面积1.6±0.3 cm²,平均压差10.5±5.4 mmHg,峰值压差18.9±9.3 mmHg。

临床怎么用

  • 对于主动脉瓣狭窄患者,快速部署AVR系统可作为手术选择之一,其5年安全性和血流动力学表现可接受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rapid deployment aortic valve replacement (AVR) has been developed to facilitate minimally invasive approaches for cardiac surgery and shorten procedural times. TRITON is a prospectively designed study to assess safety and efficacy of rapid deployment AVR with Edwards INTUITY valve system. This report presents the 5-year outcomes of the TRITON trial. METHODS: A total of 295 patients with aortic valve stenosis were enrolled in the TRITON trial and 287 patients received the study valve. Procedural, early (≤30 days) and late (>30 days) outcomes were collected. Valve haemodynamic performance was evaluated at specified time points by an independent Echocardiography Core Laboratory and clinical events adjudicated by an independent Clinical Events Committee. RESULTS: Mean age was 75.3 ± 6.7 years. A total of 158 patients underwent isolated AVR and 129 patients underwent AVR with concomitant procedures. The 5-year survival rates were 85.7 ± 3.4% and 75.2 ± 4.9% for isolated AVR and concomitant AVR, respectively. Overall, freedom from valve-related death at 5 years was 98.2 ± 0.8%. At 5 years, the valve effective orifice area was 1.6 ± 0.3 cm 2 , mean gradient was 10.5 ± 5.4 mmHg and peak gradient was 18.9 ± 9.3 mmHg. CONCLUSIONS: The 5-year outcomes of the TRITON trial demonstrate acceptable long-term safety and excellent haemodynamic performance of rapid deployment AVR with the Edwards INTUITY valve system. CLINICALTRIALS.GOV: NCT01445171.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Laufer G, Haverich A, Andreas M, et al. Long-term outcomes of a rapid deployment aortic valve: data up to 5 years. Eur J Cardiothorac Surg. 2017. PMID: 28453629. doi:10.1093/ejcts/ezx103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。